Phase 1/2 study of everolimus in advanced hepatocellular carcinoma (pages 5094–5102)
Andrew X. Zhu, Thomas A. Abrams, Rebecca Miksad, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Hui Zheng, Alona Muzikansky, Jeffrey W. Clark, Eunice L. Kwak, Deborah Schrag, Kathryn R. Jors, Charles S. Fuchs, A. John Iafrate, Darrell R. Borger and David P. Ryan
Version of Record online: 27 APR 2011 | DOI: 10.1002/cncr.26165
Everolimus was well tolerated in patients with advanced hepatocellular carcinoma, and 10 mg/day was defined as the phase 2 dosage. Preliminary antitumor activity was observed with everolimus in patients with advanced hepatocellular carcinoma, most of whom had prior systemic treatment.